Susquehanna Fundamental Investments LLC Purchases New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Susquehanna Fundamental Investments LLC purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 130,443 shares of the company's stock, valued at approximately $882,000.

A number of other institutional investors also recently made changes to their positions in the stock. Farther Finance Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock valued at $176,000 after buying an additional 1,875 shares in the last quarter. Wedmont Private Capital lifted its position in shares of Recursion Pharmaceuticals by 10.6% during the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company's stock valued at $144,000 after acquiring an additional 2,000 shares during the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Recursion Pharmaceuticals by 28.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company's stock worth $69,000 after acquiring an additional 2,235 shares in the last quarter. Finally, Green Alpha Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 3.6% in the 4th quarter. Green Alpha Advisors LLC now owns 67,145 shares of the company's stock worth $454,000 after acquiring an additional 2,346 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on RXRX. KeyCorp reduced their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Needham & Company LLC decreased their target price on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday. Morgan Stanley cut their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $7.60.

Recursion Pharmaceuticals Stock Down 12.6 %

Shares of RXRX traded down $0.60 during trading hours on Tuesday, reaching $4.16. The company's stock had a trading volume of 31,513,975 shares, compared to its average volume of 12,649,420. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -2.72 and a beta of 0.99. The company has a 50 day moving average of $5.75 and a two-hundred day moving average of $6.73. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.39) EPS. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.